The Food and Drug Administration has approved Xelpros (latanoprost ophthalmic emulsion; Sun Pharma) 0.005% for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Xelpros contains latanoprost, a prostaglandin F2α analogue that is believed to reduce IOP by increasing the outflow of aqueous humor. It is the first formulation of latanoprost that does not contain benzalkonium chloride, as the product was developed using proprietary Swollen Micelle Microemulsion technology.
The approval of Xelpros was based on randomized, controlled clinical trials involving patients with open-angle glaucoma or ocular hypertension with a mean baseline IOP of 23-26mmHg. The mean IOP-lowering effect of Xelpros administered once daily in the evening was up to 6-8mmHg.
Xelpros will be supplied as a 2.5mL emulsion filled in a 5mL bottle. Each mL contains 50mcg of latanoprost.
For more information visit myxelpros.com.